Congresses

Titlesort ascending Year
Repurposing beta-lactams for buruli ulcer treatment 2018
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
Repurposing Beta-lactams for Buruli Ulcer Therapy, from the Bench to the Clinic 2022
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria 2020
Régimen con betalactámicos para reducir el tratamiento de la úlcera de Buruli: tratamiento estándar de 8 semanas (rifampicina más claritromicina) versus 4 semanas de tratamiento estándar más amoxicilina/clavulanato [RC8 vs. RCA4] (ensayo clínico BLMs4BU) 2022
Recapitulation of pulmonary SARS-CoV-2 infection in vitro in a novel 3D human lung organoid model with innate immune and stromal cells 2022
Preliminary studies to elucidate the mode of action of a new chemical series with antimicrobial activity 2018
PRELIMINARY STUDIES FOR THE ELUCIDATION OF THE MODE OF ACTION OF THE AVERMECTINS AS ANTI-TB AGENTS 2019
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
OPTIKA – a new high content drug combination dynamic assay / Hollow-fibre models 2022
Nuevos métodos para la búsqueda de combinaciones sinérgicas 2019
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
New methodologies to test antibiotic susceptibility against emerging pathogens in cystic fibrosis 2019
Multicentric in-vitro characterization of MPL-204, a new anti- tuberculosis drug candidate, by the ERA4TB collaborative initiative 2022
Mode of action elucidation studies of the avermectins against Mycobacteria 2019
Mode of action elucidation studies of a new chemical series active against Mycobacteria and other microbial pathogens 2019
Mathematical model of meropenem against Mycobacterium tuberculosis 2019

Pages